

Table 1. Baseline characteristics of the patients.

Age, years	46 (40-57)
Male sex, n (%)	4 (36.4)
Follow-up, months	35 (24-36.5)
BMI, kg/m ²	23 (22-25)
HCV genotype, n (%)	
1	1 (9.1)
2	1 (9.1)
3	5 (45.4)
4	4 (36.4)
Chelation agent, n (%)	
Deferoxamine	4 (36.4)
Deferiprone	1 (9.1)
Deferasirox	1 (9.1)
Deferoxamine + Deferiprone	5 (45.4)
Cirrhosis, n (%)	4 (36.4)
Splenectomy, n (%)	8 (72.7)
MRI Liver Iron Concentration a, µg/g dry weight	4.2 (2.6-7.9)
IFN-experienced, n (%)	7 (63.6)
Fibroscan, kPa	10.3 (6.1-14.6)
AST, iu/ml	39 (35-76)
ALT, iu/ml	77 (33-138)
Bilirubin total, mg/dl	1.7 (1.4-2.5)
Albumin, g/l	45 (42-47)
Hemoglobin, g/l	10 (9.5-11.2)
Platelet count, x10 ⁹ /l	435 (258-506)
Diabetes, n (%)	2 (18.2)
Heart Disease, n (%)	4 (36.4)
Osteoporosis, n (%)	5 (45.4)
Hypogonadism, n (%)	6 (54.5)
Thyroidopathy, n (%)	5 (45.4)

Notes: Quantitative values are presented as median (interquartile range). a Data available on 6 patients.

Abbreviations: HCV, hepatitis C virus; BMI, body mass index; IFN, interferon; MRI, magnetic resonance imaging; ALT, alanine aminotransferase; AST, aspartate aminotransferase.